Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis

.
Source: Expert Opinion on Drug Discovery - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Conclusions: Including selected drugs in risk adjustment improved the models’ predictive power. In addition, inclusion of selected drugs may discourage insurers from using formulary and drug benefit design to avoid enrollment of patients taking high-cost drugs, such as for HIV, multiple sclerosis, and rheumatoid arthritis, and improve access for enrollees taking these drugs. Adding RXCs also may improve plan risk measurement for plans with less complete diagnosis reporting.
Source: Medical Care - Category: Health Management Tags: Original Articles Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Elizabeth S. Gromisch, Joseph F. Kulas, Hamada Altalib, Robert D. Kerns, Kristin M. Mattocks, Cynthia A. Brandt, Sally Haskell
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Andréa Gomes Moraes, Silvia Gonçalves Ricci Neri, Robert W. Motl, Carlos Bernardo Tauil, Felipe von Glehn Silva, Éber Castro Corrêa, Ana Cristina de David
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Living in highly polluted urban areas is associated with a greater risk of developing multiple sclerosis than living in less polluted areas, a large population-based study suggests.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including in the CNS and the immune system. Whether bile acid metabolism is abnormal in MS is unknown. Using global and targeted metabolomic profiling, we identified lower levels of circulating bile acid metabolites in multiple cohorts of adult and pediatric patients with MS compared with controls. In white matter lesions from MS brain tissue, we noted the presence of bile acid receptors on immune and glial cells. To mechanistically examine the ...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): S. El-Wahsh, H. Bogaardt, F. Kumfor, K. Ballard
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Juan Zhang, Yong-Feng Xu, Lei Wu, Hong-Fu Li, Zhi-Ying Wu
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): A Droby, L Fleysher, M Petracca, K Podranski, J Xu, M Fabian, M MarjaĊ„ska, M Inglese
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Kejia Zhang, Yinlong Zhao, Zhenzhen Liang, Chunpeng Wang, Xin Liu
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 25 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Guillermo Delgado-García, Emmanuel Antonio-Luna, Diego López-Mena, Verónica Rivas-Alonso, José Flores-Rivera, Teresa Corona-Vázquez
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Drugs & Pharmacology | Gilenya | Multiple Sclerosis